Inflammatory response of mouse skin exposed to the very potent carcinogen dibenzo[a,l]pyrene: A model for tumor promotion

Fundamental and Applied Toxicology

Volumn 36, Issue 1, 1997, Pages 71-78

  Casale, George P ^a   Higginbotham, Sheila ^a   Johansson, Sonny L ^a,b   Rogan, Eleanor G ^a   Cavalieri, Ercole L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; DIBENZO[A,L]PYRENE; DRUG METABOLITE; POLYCYCLIC AROMATIC HYDROCARBON; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTACT ALLERGY; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMPARISON; EPIDERMIS HYPERPLASIA; ERYTHEMA; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; TOXICOKINETICS;

EID: 26844505192     PISSN: 02720590     EISSN: None     Source Type: Journal    
DOI: 10.1006/faat.1997.2291     Document Type: Article

References (22)

1. Albert, R. E., Miller, M. L., Cody, T., Andringa, A., Shukla, R., and Baxter, C. S. (1991). Benzo[a]pyrene-induced skin damage and tumor promotion in the mouse. Carcinogenesis 12, 1273-1280.
2. Aldaz, C. M., Conti, C. J., Gimenez, I. B., Slaga, T. J., and Klein-Szanto, A. J. P. (1985). Cutaneous changes during prolonged application of 12-O-tetradecanoylphorbol-13-acetate on mouse skin and residual effects after cessation of treatment. Cancer Res. 45, 2753-2759.
3. Asherson, G. L., and Ptak, W. (1968). Contact and delayed hypersensitivity in the mouse. I. Active sensitization and passive transfer. Immunology 15, 405-416.
4. Bock, F. G., Fjelde, A., Fox, H. W., and Klein, E. (1969). Tumor promotion by 1-fluoro-2,4-dinitrobenzene, a potent skin sensitizer. Cancer Res. 29, 179-182.
5. Cavalieri, E. L., Higginbotham, S., RamaKrishna, N. V. S., Devanesan, P. D., Todorovic, R., Rogan, E. G., and Salmasi, S. (1991). Comparative dose-response tumorigenicity studies of dibenzo[a,l]pyrene versus 7,12-dimethylbenz[a]anthracene, benzo[a]pyrene and two dibenzo[a,l]pyrene dihydrodiols in mouse skin and rat mammary gland. Carcinogenesis 12, 1939-1944.
6. Devanesan, P. D., Cremonesi, P., Nunnally, J. E., Rogan, E. G., and Cavalieri, E. L. (1990). Metabolism and mutagenicity of dibenzo[a,e]pyrene and the very potent environmental carcinogen dibenzo[a,l]pyrene. Chem. Res. Toxicol. 3, 580-586.
7. DiGiovanni, J. (1992). Multistage Carcinogenesis in mouse skin. Pharmacol. Ther. 54, 63-128.
8. Dvorak, H. F., Mihm, M. C., Dvorak, A. M., Johnson, R. A., Manseau, E. J., Morgan, E., and Colvin, R. B. (1974). Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab. Invest. 31, 111-130.
9. Fjelde, A., and Turk, J. L. (1965). Induction of an immunological response in local lymph nodes by chemical carcinogens. Nature 205, 813-815.
10. Gill, H. S., Kole, P. L., Wiley, J. C., Li, K.-M., Higginbotham, S., Rogan, E. G., and Cavalieri, E. L. (1994). Synthesis and tumor-initiating activity in mouse skin of dibenzo[a,l]pyrene syn-and anti-fjord-region diol epoxides. Carcinogenesis 15, 2455-2460.
11. Higginbotham, S., RamaKrishna, N. V. S., Johansson, S. L., Rogan, E. G., and Cavalieri, E. L. (1993). Tumor-initiating activity and carcinogenicity of dibenzo[a,l]pyrene versus 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene at low doses in mouse skin. Carcinogenesis 14, 875-878.
12. Kenna, J. G., Neuberger, J., and Williams, R. (1987). Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J. Pharmacol. Exp. Ther. 242, 733-740.
13. Kenna, J. G., Satoh, H., Christ, D. D., and Pohl, L. R. (1988). Metabolic basis for a drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 245, 1103-1109.
14. Kenna, J. G., Martin, J. L., Satoh, H., and Pohl, L. R. (1990). Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab. Disp. 18, 788-793.
15. Kitagaki, H., Fujisawa, S., Watanabe, K., Hayakawa, K., and Shiohara, T. (1987). Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice. J. Invest. Dermatol. 105, 749-755.
16. Klemme, J. C., Mukhtar, H., and Elmets, C. A. (1987). Induction of contact hypersensitivity to dimethylbenz(a)anthracene and benzo(a)pyrene in C3H/HeN mice. Cancer Res. 47, 6074-6078.
17. LaVoie, E. J., He, J.-M., Meegalla, R. L., and Weyand, E. H. (1993). Exceptional tumor-initiating activity of 4-fluorobenzo[j]fluoranthene on mouse skin: Comparison with benzo[j]-fluoranthene, 10-fluoro-benzo[j]-fluoranthene, benzo[a]pyrene, dibenzo[a,l]pyrene and 7,12-dimethylbenz[a]anthracene. Cancer Lett. 70, 7-14.
18. NIH Publication No. 81-2385 (1981). NIH Guidelines for the Laboratory Use of Chemical Carcinogens. U.S. Government Printing Office, Washington, DC.
19. Raick, A. N. (1973). Ultrastructural, histological, and biochemical alterations produced by 12-O-tetradecanoyl-phorbol-13-acetate on mouse epidermis and their relevance to skin tumor promotion. Cancer Res. 33, 269-286.
20. Scribner, N. K., and Scribner, J. D. (1980). Separation of initiating and promoting effects of the skin carcinogen 7-bromomethylbenz(a)anthracene. Carcinogenesis 1, 97-100.
21. Turk, J. L., and Stone, S. H. (1963). Implications of the cellular changes in lymph nodes during the development and inhibition of delayed type hypersensitivity. In Cell-Bound Antibodies (B. Amos and H. Koprowski, Eds.), pp. 51-60. Wistar Institute Press, Philadelphia.
22. Van Duuren, B. L. (1969). Tumor-promoting agents in two-stage Carcinogenesis. Prog. Exp. Tumor Res. 11, 31-68.